Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

PHASE4CompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Risperidone microspheres

Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.

DRUG

Risperidone

Target dose is 4 mg/day.

DRUG

Olanzapine

Target dose is 15 mg/day.

DRUG

Quetiapine

Target dose is 600 mg/day.

DRUG

Ziprasidone

Target dose is 120 mg/day.

DRUG

Aripiprazole

Target dose is 20 mg/day.

DRUG

Paliperidone

Target dose is 6 mg/day.

Trial Locations (8)

11004

The Zucker Hillside Hospital, Glen Oaks

52242

University of Iowa College of Medicine, Psychiatry Research, Iowa City

68131

Creighton University, Omaha

87131

University of New Mexico, Albuquerque

91344

University of California, Los Angeles, Los Angeles

30912-3800

Medical College of Georgia, Department of Psychiatry, Augusta

02114

Harvard Medical School -- Massachusetts General Hospital, Boston

02720

Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center, Fall River

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Northwell Health

OTHER

NCT00330863 - Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy | Biotech Hunter | Biotech Hunter